Search filters

Filters
Clear All

Phase

  • 5
  • 3
  • 4
  • 2
  • 1
  • 6
  • 24
  • 15
  • 24

Found 24 Multiple Sclerosis trials

A listing of Multiple Sclerosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

18 years - 99 years
All genders
Observational
Adult patients with Rheumatoid Arthritis, Psoriatic Arthritis, SLE, Sjogren’s Disease, Multiple Sclerosis, Scleroderma, Vasculitis or Blistering Diseases will undergo a blood draw and collection of clinical information prior to receipt of COVID-19 vaccination. Subjects will undergo a repeat blood draw and collection of clinical information at 4-10 weeks, 6 months …
99 years or below
All genders
This study will evaluate the pharmacokinetics of ocrelizumab in the breastmilk of lactating women with CIS or MS (in line with the locally approved indications) treated with ocrelizumab, by assessing the concentration of ocrelizumab in mature breastmilk, as well as the corresponding exposure and pharmacodynamic effects (blood B cell levels) …
18 years - 50 years
All genders
Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced -cell mass contributes to the insulin secretory defects that characterizes cystic fibrosis-related diabetes (CFRD), other modifiable determinants appear operative in the emergence and progression of abnormal glucose tolerance towards diabetes. Identifying interventions …
 Investigation of the Effect of Branched Chain Amino Acids on Fat-Induced Insulin Resistance in Healthy Adults.
18 years - 39 years
All genders
Phase 1
Elevations in plasma levels of branched chain amino acids (BCAAs, comprising leucine, valine, and isoleucine), a large component of protein, are strongly associated with insulin resistance and type 2 diabetes, but mechanisms for this relationship are unclear. This protocol will determine whether excess BCAAs worsen free fatty acid-induced insulin resistance. …
99 years or below
All genders
Phase 1
This is a Phase 1/2, open-label, multicenter dose-escalation and dose-expansion trial evaluating the safety and tolerability of fimepinostat administered orally to patients with R/R lymphoma.
99 years or below
All genders
Phase 3
The study is an open-label, randomized, parallel group study conducted in patients with histologically confirmed MPM of epithelioid or biphasic (predominantly [50%] epithelioid) histology who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum …
99 years or below
All genders
This study aims to investigate the benefits of collecting lymph in addition to blood in patients with multiple sclerosis (MS). It is now well recognized that the central nervous system (CNS) is not as immune privileged as it has been considered. A system of lymphatic drainage has been described both …
 NEUROIMMUNOLOGY PATIENT RESPONSE TO COVID-19 OUTBREAK
18 years - 99 years
Accepts healthy volunteer
All genders
The purpose of this research study is to understand how our patients with Multiple Sclerosis (MS) and other neuroimmune disorders are being affected by the COVID-19 outbreak. We want to understand how susceptible our patients are to COVID-19. We also want to evaluate the longer-term social and psychological consequences of …
 Healthy volunteers for Neuroinflammatory research study
18 years - 60 years
Accepts healthy volunteer
All genders
We are conducting research studies on how immune system cells contribute to inflammatory conditions of the nervous system, such as multiple sclerosis, neuromyelitis optica (NMO), encephalitis, head injury, epilepsy, Parkinson's disease (PD), Alzheimer's disease (AzD), Lou Gherig's disease (amyotrophic lateral sclerosis; ALS) frontotemporal dementia (FTD) and others. This includes investigating …
99 years or below
All genders
Phase 1
This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose escalation study of AMG 176 administered IV in subjects with relapsed or refractory multiple myeloma and subjects with relapsed or refractory AML.
11 - 20 of 24